FDA’s “Dear Doc” Final Guidance Yields To One Industry Request, Denies Another
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency offers a sneak peek into final “Dear Health Care Provider Letters” guidance, decreasing some of industry’s burden, while refusing to cave on other requirements.
You may also be interested in...
How To Write An Effective Letter: FDA Advises Sponsors On Crafting Drug Alerts
Guidance on “Dear Doctor” letters says companies should evaluate the effectiveness of their communications – but solely for their own use.
FDA Standardizing “Dear Doc” Letters To Fix Problems With Recipients As Much As Senders
FDA appears to have found problems on both the senders’ and recipients’ sides of “Dear Health Care Provider Letters” and issued guidance recommending effectiveness assessments and formatting specifications in an attempt to give the correspondence more impact.
FDA Wants To Consult Before Manufacturers Send "Dear Doc" Letters
New draft guidance says talks will ensure information and target audience are correct. Letters also will take on a more standard format.